Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Published on December 19, 2024

cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the third quarter of

Continue reading on website
Other news

Donald Trump’s spokesperson confirmed that the president-elect will work with Javier Milei for free trade

December 19, 2024
Donald Trump government Help Argentina achieve a new agreement with the International Monetary Fund (IMF). In an interview with the renowned

LION ELECTRIC OBTAINS CREDITOR PROTECTION UNDER CCAA

December 19, 2024
financing (the "DIP Financing") provided by the lenders under the Company's syndicated senior revolving credit agreement in order to fund